QTTB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

3 Analyst Rating

Wall Street analysts forecast QTTB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTTB is 15.00 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 3.050

Low

10.00

Averages

15.00

High

20.00

Current: 3.050

Low

10.00

Averages

15.00

High

20.00

Wells Fargo

Derek Archila

Hold

Maintains

$16 → $15

2025-03-12

Reason

Wells Fargo

Derek Archila

Price Target

$16 → $15

2025-03-12

Maintains

Hold

Reason

Piper Sandler

Christopher Raymond

Buy

Hold

Downgrades

$20 → $4

2025-02-11

Reason

Piper Sandler

Christopher Raymond

Price Target

$20 → $4

2025-02-11

Downgrades

Buy

Hold

Reason

Piper Sandler downgraded Q32 Bio to Neutral from Overweight with a price target of $4, down from $20. The firm is surprised by the company's decision to discontinue complement inhibitor ADX-097 before presenting data from the drug's renal basket study. The best course of action is to move to Neutral on the name until a better picture of bempikibart's efficacy profile in alopecia areata emerges, the analyst tells investors in a research note.

BMO Capital

Etzer Darout

Buy

Hold

Downgrades

$22 → $3

2025-02-11

Reason

BMO Capital

Etzer Darout

Price Target

$22 → $3

2025-02-11

Downgrades

Buy

Hold

Reason

BMO Capital downgraded Q32 Bio to Market Perform from Outperform with a price target of $3, down from $22. The company announced an internal restructuring, discontinuing development of its main value driver, ADX-097, to focus on bempikibart development in patients with alopecia areata, the analyst tells investors in a research note. The firm says that while te decision seems to signal confidence in bempikibart, the drug's early clinical profile is not compelling enough to merit meaningful value beyond what it already assumes. As such, it removed contributions from ADX-097 and downgraded the shares.

Valuation Metrics

The current forward P/E ratio for Q32 Bio Inc (QTTB.O) is -0.51, compared to its 5-year average forward P/E of -4.29. For a more detailed relative valuation and DCF analysis to assess Q32 Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.29

Current PE

-0.51

Overvalued PE

-0.92

Undervalued PE

-7.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 242.3% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 242.3% over the last month.

Sold

Bought

QTTB News & Events

Events Timeline

No data

News

8.5

12-02NASDAQ.COM

Q32 Bio Transfers ADX-097, a Complement Inhibitor, to Akebia Therapeutics

4.5

12-01Benzinga

Crude Oil Rises More Than 1%; November Sees Decline in ISM Manufacturing PMI

4.5

12-01Benzinga

Dow Falls 200 Points; Q32 Bio Stock Soars

People Also Watch

Frequently Asked Questions

What is Q32 Bio Inc (QTTB) stock price today?

The current price of QTTB is 3.05 USD — it has increased 3.04 % in the last trading day.

What is Q32 Bio Inc (QTTB)'s business?

Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.

What is the price predicton of QTTB Stock?

What is Q32 Bio Inc (QTTB)'s revenue for the last quarter?

Q32 Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Q32 Bio Inc (QTTB)'s earnings per share (EPS) for the last quarter?

Q32 Bio Inc. EPS for the last quarter amounts to -0.90 USD, decreased -85.78 % YoY.

What changes have occurred in the market's expectations for Q32 Bio Inc (QTTB)'s fundamentals?

The market is revising No Change the revenue expectations for QTTB for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 62.23%.

How many employees does Q32 Bio Inc (QTTB). have?

Q32 Bio Inc (QTTB) has 42 emplpoyees as of December 16 2025.

What is Q32 Bio Inc (QTTB) market cap?

Today QTTB has the market capitalization of 0.00 USD.